<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813199</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-301</org_study_id>
    <nct_id>NCT03813199</nct_id>
  </id_info>
  <brief_title>Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>Phase IIa Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to an Anti- Tumor Necrosis Factor Alpha (Tnfα) Therapy, or Intolerance to Anti-Tnfα Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of
      ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to
      severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one
      or more anti- tumor necrosis factor alpha (TNFα) therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter study. The study will
      consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase.

      Approximately 60 participants with active Rheumatoid Arthritis will be randomly assigned to
      receive placebo, 50mg ABX464 or 100mg ABX464 during the treatment phase.

      The maximum period of active treatment will be 12 weeks. The maximum duration of study
      participation will be 17 weeks.

      Participant safety will be monitored throughout the study. In addition, several experimental
      and clinical endpoints will be assessed to obtain information on preliminary efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events in the ABX464 treated Patients versus placebo, categorized by severity</measure>
    <time_frame>through study completion, an average of 15 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ACR20 response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The categorical American College of Rheumatology 20% (ACR20) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% improvement in the ACR response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the individual components of ACR response</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>American College of Rheumatology (ACR) criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Scores (DAS) (28 joints) [DAS28]</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. The DAS28 assessment include 28 tender and swollen joint counts (TJC and SJC), acute phase reactant (CRP or ESR), and patient's global assessment of disease activity (PtGA).
DAS28-ESR = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.70 Ln [ESR(mm/h)] + 0.014 PtGA(VAS100mm) DAS28-CRP = 0.56 √ (TJC28) + 0.28 √ (SJC28) + 0.36 Ln [CRP(mg/L)+1] + 0.014 PtGA(VAS100mm) + 0.96 Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simplified Disease Activity Index Score (SDAI)</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>SDAI is a validated index of rheumatoid arthritis disease activity. The SDAI calculation is based on 28 tender and swollen joint counts, C-Reactive Protein (CRP), patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA).
SDAI = tender28 + swollen28 + CRP + (PtGA/10) + (PrGA/10). A moderate activity is defined by a SDAI &gt;11 to 26 included. A high activity is defined by a SDAI &gt;26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Disease Activity Index Score (CDAI)</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>CDAI is a validated index of rheumatoid arthritis disease activity. The CDAI calculation is based on 28 tender and swollen joint counts, patient's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PrGA).
CDAI = tender28 + swollen28 + (PtGA/10) + (PrGA/10). A moderate activity is defined by a CDAI &gt;10 to 22 included. A high activity is defined by a CDAI &gt;22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ACR20/50/70 response</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>Proportion of patients who achieved at least 20%, 50% or 70% improvement in the American College of Rheumatology (ACR) response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving DAS28-CRP response</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>Proportion of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) [DAS28-CRP] response will be measured as moderate/good European League Against Rheumatism (EULAR) response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Low Disease Activity (LDA)</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>Low Disease Activity (LDA) is defined as DAS28-ESR &lt;=3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Disease Activity Score (DAS) DAS28-Erythrocyte Sedimentation Rate (ESR) [DAS28-ESR] remission</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>DAS28-ESR remission is defined as DAS2-ESR &lt; 2.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Simplified Disease Activity Score (SDAI) remission</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>The SDAI remission is considered achieved if the SDAI score ≤ 3.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving Clinical Disease Activity (CDAI) remission</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>The CDAI remission is considered achieved if the CDAI score ≤ 2.8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission</measure>
    <time_frame>Week 2, Week 4, Week 8 and Week 12</time_frame>
    <description>The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ABX464 50mg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks
+ methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABX464 100mg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks
+ methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive two capsules of matching placebo once daily for 12 weeks
+ methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464 50mg</intervention_name>
    <description>ABX464 is a new anti-inflammatory drug</description>
    <arm_group_label>ABX464 50mg + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>placebo matching with ABX464</description>
    <arm_group_label>ABX464 50mg + methotrexate</arm_group_label>
    <arm_group_label>Placebo + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464 100mg</intervention_name>
    <description>ABX464 is a new anti-inflammatory drug</description>
    <arm_group_label>ABX464 100mg + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study</description>
    <arm_group_label>ABX464 100mg + methotrexate</arm_group_label>
    <arm_group_label>ABX464 50mg + methotrexate</arm_group_label>
    <arm_group_label>Placebo + methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a confirmed and documented diagnosis of adult-onset rheumatoid arthritis,
             for at least 12 weeks, according to the revised 2010 American College of Rheumatology-
             European League Against Rheumatism (ACR-EULAR) classification criteria, including at
             least one positive criteria among the following: Rheumatoid Factor (RF),
             Anti-Citrullinated Peptide Antibody (ACPA) or bone erosion;

          -  Swollen joint count (SJC) of ≥ 4 (28-joint count) and tender joint count (TJC) ≥4
             (28-joint count) at screening;

          -  Patient with a moderate to severe disease activity score Disease Activity Score (28
             joints) C-Reactive Protein [DAS28 CRP] ≥ 3.2 and C-reactive Protein (CRP) ≥ 5 mg/L (≥
             4.76 nmol)/L) at screening;

          -  Patient who had an inadequate response (IR), or failed either methotrexate (MTX)
             or/and anti- Tumor Necrosis Factor alpha (TNFα) therapy (both administered for at
             least 12 weeks before IR) or were intolerant to anti- TNFα therapy.

        Exclusion Criteria:

          -  Patient with a known positive anti-double stranded deoxyribonucleic acid (DNA
             [anti-dsDNA]) and confirmed diagnosis of systemic lupus erythematosus (SLE);

          -  Patient with known active infections at screening such as CytoMegaloVirus (CMV),
             herpes virus and/or recent infectious hospitalization;

          -  Acute, chronic or history of clinically relevant pulmonary, cardiovascular, hepatic,
             pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable
             Central Nervous System (CNS) pathology such as seizure disorder, angina or cardiac
             arrhythmias, active malignancy or any other clinically significant medical problems as
             determined by physical examination and/or laboratory screening tests and/or medical
             history;

          -  Acute, chronic or history of immunodeficiency or other autoimmune disease;

          -  Patient previously treated with any non-anti-TNF biological Disease-Modifying
             AntiRheumatic Drugs (bDMARDs), and targeted DMARDs (tDMARDS) prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul GINESTE, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abivax S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul GINESTE, PharmD</last_name>
    <phone>+33 1 5383 0961</phone>
    <email>paul.gineste@abivax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Marc STEENS, MD</last_name>
    <phone>+33 1 5383 0961</phone>
    <email>Jean-marc.steens@abivax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filip Van den Bosch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Filip Van den Bosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peggy Jacques, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rik Joos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rik Joos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Tomayerova nemocnice</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Kopsa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Petr Kopsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Filkova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Filkova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hôpital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire Cormier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Grégoire Cormier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Varin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaigneux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caulier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cozic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Daien, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire DAIEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Medical Centre - Déli Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Rojkovich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernadette Rojkovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zsolt Pápai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd.</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katalin Fazekas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Katalin Fazekas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMed Rehabilitációs és Diagnosztikai Központ</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tünde Varga, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tünde Varga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kata Kerekes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imola Miklovicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp. J.</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Daniluk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Daniluk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Urszula Jafiszow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Maria Jarmoc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Witkowska-Trojniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nonna Anna Nowak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Bagrowska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia MCM</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Korkosz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariusz Korkosz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bożena Jachimczak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa Górecka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zespół Poradni Specjalistycznych REUMED</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Chudzik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dariusz Chudzik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Zakrzewski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobiasz Kardas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Kolarz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cezary Stępniak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED S.C.</name>
      <address>
        <city>Nadarzyn</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmańska</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Leszczyński, MD</last_name>
    </contact>
    <investigator>
      <last_name>Piotr Leszczyński, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Pawlak-Buś, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Torzyńska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarosław Domański, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Geriatrics</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brygida Kwiatkowska, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brygida Kwiatkowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Maślińska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Dmowska-Chalaba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kinga Kostyra-Grabczak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Jakubaszek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RHEUMA MEDICUS Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

